Articles related to BIOMARKERS
miR-3156-5p is Downregulated in Serum of MEN1 Patients and Regulates Expression of MORF4L2
The authors engaged in research to attempt to identify circulating biomarkers for pancreatic NETs, to improve tumor surveillance and quality of life. They examined the expression of circulating miRNA in the serum of MEN1 patients and found an inverse relationship between miR-3156-5p and MORF4L2 expression, representing a potential serum biomarker that could facilitate the detection of NET occurrence in MEN1 patients.
Endocrinology, Diabetes, Metabolism August 22nd 2022
Serum Neurofilament Light Chain (sNfl) in the Prognosis of Disease Activity in Relapsing Multiple Sclerosis
Panelists conclude that sNfL can be used as a biomarker to assess response totreatment in future trials. In the clinic setting, it could become valuable in directingtherapy; for example, in cases in which the patient is absent clinical signs of aggressiveMS and it’s unclear if they will benefit from infused, injected, or oral disease-modifyingtherapy.
Neurology August 16th 2022
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial
Selecting effective antidepressants for the treatment of major depressive disorder is an imprecise practice. With remission rates of about 30% after the initial therapy selection, there is a need to uncover biomarkers able to predict treatment response. This study looked at pharmacogenomic testing for drug-gene interactions to guide treatment selection. Unfortunately, they did not find significantly improved outcomes.
Psychiatry July 19th 2022
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A
Immune checkpoint inhibitor (ICI)-refractory cancers are arguably one of the greatest unmet needs in oncology. In this randomized phase II substudy, patients ineligible for a biomarker-matched previously treated with ICI and platinum-based chemotherapy and progressive disease at least 84 days after initiation of ICI were randomly assigned to receive ramucirumab plus pembrolizumab (RP) or investigator’s choice standard of care (SOC: docetaxel/ramucirumab, docetaxel, gemcitabine, and pemetrexed). The study’s primary objective was to compare overall survival (OS). The median OS was 14.5 months for RP and 11.6 months for SOC. Docetaxel and ramucirumab were the most common SOC, received by 2/3 of patients. This randomized phase II trial demonstrated significantly improved OS with RP compared with SOC in patients with advanced NSCLC previously treated with ICI and chemotherapy.
Oncology, Medical June 27th 2022
CME: Practicing Precision in ALK and ROS1 Rearrangement Positive Non-Small Cell Lung Cancer (NSCLC): Testing, Targets, and Treatments
This one-credit activity features an expert panel providing their perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.
Oncology, Medical May 25th 2022